Inhibiting Key Molecular Chaperone Sensitives Tumors to Radiation Therapy in Animal Models – University of Michigan Health System News

The molecular chaperone protein known as heat shock protein 90 (Hsp90) helps stabilize a number of proteins that are involved in tumor growth. This is why inhibitors that act on the protein have been investigated as potential anti-cancer drugs.

So far, however, the inhibitors developed by various academic groups and pharmaceutical companies have met with limited success due to their high toxicity to normal cells.

Now, a new animal model study from the University of Michigan Rogel Cancer Center suggests Hsp90 inhibitors could help treat cancer in an indirect way. A low dose of a Hsp90 inhibitor known as AT13387 (onalespib) was able to sensitize tumors to radiation therapy, according to findings published in Clinical Cancer Research.

To the best of our knowledge, our study is the first to demonstrate that a sub-cytotoxic concentration of an Hsp90 inhibitor can inhibit the DNA repair process and thus selectively sensitize tumors to radiotherapy, says study senior author Mukesh Nyati, Ph.D., an associate professor of radiation oncology at Michigan Medicine.

The approach led to significant reduction in tumor growth in mouse xenograft models of head and neck squamous cell carcinoma and pancreatic cancer.

The Hsp90 inhibitor compound used in the study was provided by the Cancer Therapy Evaluation Program at the National Institutes of Health.

Paper cited: Low dose Hsp90 inhibitor selectively radiosensitizes HNSCC and Pancreatic xenografts, Clinical Cancer Research. DOI: 10.1158/1078-0432.CCR-19-3102

Read more:

Inhibiting Key Molecular Chaperone Sensitives Tumors to Radiation Therapy in Animal Models - University of Michigan Health System News

AGC to Complete the Acquisition of MolMed on July 31, 2020 – BioSpace

AGC Biologics adds leading-edge cell & gene therapy company in Milan, Italy

SEATTLE, July 27, 2020 /PRNewswire/ -- AGC Biologics, a Global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that they will acquire the majority of the share capital of Molecular Medicine S.p.A. ("MolMed") on July 31, 2020. MolMed is a biotechnology company focused on research, development, production and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases. AGC Biologics is now one of the very few CDMO's in the world offering both plasmid production and end-to-end cell and gene therapy services.

Cell and gene therapy is an innovative and rapidly growing therapeutic field that aims to treat diseases that do not have adequate treatments to date. Approximately 1,000 clinical trials are underway worldwide, with some products receiving market authorization in the last few years and approximately 50 new therapies expected to be authorized by 2030. Thanks to its two commercially authorized facilities, MolMed offers GMP services for the development and production of cell and gene therapies. MolMed brings deep experience and expertise in providing development and GMP manufacturing services for viral vectors and genetically modified cells, from the preclinical phase through commercial demand.

"While we work hard to take care of each other and our customers during this very challenging and uncertain time, it's also important that we ensure the continued growth of our company," says AGC Biologics CEO Patricio Massera. "AGC Biologics is committed to continuously expanding our offerings and growing our capacity to serve all the needs of current and future customers. We are very pleased to be adding MolMed and its great cell and gene therapy capabilities and track record to AGC Biologics' global CDMO service offerings."

About AGC Biologics:AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO) with a strong commitment to deliver the highest standard of service to clients and partners. The company currently employs more than 1,000 employees worldwide. AGC Biologics' global network spans three continents, with cGMP-compliant facilities in Seattle, Washington; Boulder, Colorado; Copenhagen, Denmark; Heidelberg, Germany; and Chiba, Japan.

AGC Biologics offers deep industry expertise and unique customized services for the scale-up and cGMP manufacture of protein-based therapeutics, from pre-clinical to commercial mammalian and microbial production. Integrated service offerings include plasmid (GMP pDNA) manufacturing, cell line development, bioprocess development, formulation, analytical testing, antibody drug development and conjugation, cell banking and storage and protein expression, including the proprietary CHEF1 Expression System for mammalian production. Learn more at http://www.agcbio.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/agc-to-complete-the-acquisition-of-molmed-on-july-31-2020-301099750.html

SOURCE AGC Biologics

Read more:

AGC to Complete the Acquisition of MolMed on July 31, 2020 - BioSpace

Postdoctoral Researcher, Cognitive and Brain Aging Group job with UNIVERSITY OF HELSINKI | 214656 – Times Higher Education (THE)

INVITATION FOR APPLICATIONS

The Institute for Molecular Medicine Finland (FIMM) is an international research unit focusing on human genomics and personalised medicine at the Helsinki Institute of Life Science (HiLIFE) of the University of Helsinki - a leading Nordic university with a strong commitment to life science research. As part of Academic Medical Center Helsinki in Meilahti campus FIMM collaborates locally with the Faculty of Medicine, Helsinki University Hospital and National Institute for Health and Welfare. FIMM is part of the Nordic EMBL Partnership for Molecular Medicine, composed of the European Molecular Biology Laboratory (EMBL) and the centres for molecular medicine in Norway, Sweden and Denmark, and the EU-LIFE Community.

FIMM is currently seeking a postdoctoral researcher to join Cognitive and Brain Aging group

Description:

Postdoctoral researcher will be working in FIMM Cognitive and Brain Aging group led by Dr. Eero Vuoksimaa. Cognitive and Brain Aging group studies risk and protective factors of old age cognitive impairment and aims to improve early detection and diagnosis of dementia and Alzheimers Disease. We are also interested in healthy cognitive aging and cognitive reserve. Our multidisciplinary approach includes e.g., epidemiology, twins studies, molecular genetics, neuropsychology and brain imaging. We are seeking highly motivated postdoctoral researcher to work in a project that aims to understand the mechanisms of cognitive and brain aging from middle age to the oldest-old. Project is done in close collaboration with national and international researchers including Turku PET Centre and University of California, San Diego.

Postdoctoral researcher will participate in analyzing brain imaging, cognitive and genetic data, conducting statistical analyses, presenting in scientific conferences, writing of research manuscripts and in grant writing.

Qualifications and experience:

Candidates should have a PhD in neuropsychology, neurosciences, psychology, genetics or related field. Candidates with track record in processing and analyzing structural brain imaging data and/or experience in twin research / molecular genetics will be preferred. Ideal candidate has expertise also in Alzheimers disease and/or cognitive aging. Proficiency in spoken and written English is required.

Salary and contract:

The salary will be commensurate with qualifications based on the Finnish university salary (YPJ) system on previous qualifications, experience and performance in the position. The contract will be offered for one year with a possibility for extension for a second year. Full time fixed-term position is available from September 2020 or as agreed. Due to coronavirus situation the position may be started remotely.

To apply, please submit the application, together with your CV and a 1 page motivation letter, through the University of Helsinki electronic recruitment system by clicking on Apply for job. Internal applicants (i.e., current employees of the University of Helsinki) please submit your applications through the SAP HR portal.

Attach motivation letter and CV as a single PDF file. CV should include name and contact information of two referees and the list of publications with highlighting up to five most important papers and describing candidates role in these papers. Please indicate your experience in brain imaging and/or behavior/molecular genetics in the motivation letter and indicate why you want to study cognitive aging.

Please apply no later than 3.8.2020. Interviews will be conducted either in-person or online.

For further information please visit our website at http://www.fimm.fi or contact Dr Eero Vuoksimaa at eero.vuoksimaa@helsinki.fi

If you need support with the recruitment system, please contact recruitment@helsinki.fi. Please contact hr-hilife@helsinki.fi for other process-related questions.

Due date

03.08.2020 23:59 EEST

Read more here:

Postdoctoral Researcher, Cognitive and Brain Aging Group job with UNIVERSITY OF HELSINKI | 214656 - Times Higher Education (THE)

Researchers uncover how cells interact with supporting proteins to heal wounds – Washington University in St. Louis Newsroom

When we get a wound on our skin, the cells in our bodies quickly mobilize to repair it. While it has been known how cells heal wounds and how scars form, a team led by researchers from Washington University in St. Louis has determined for the first time how the process begins, which may provide new insight into wound healing, fibrosis and cancer metastasis.

The team, led by Delaram Shakiba, a postdoctoral fellow from the NSF Science and Technology Center for Engineering Mechanobiology (CEMB) at the McKelvey School of Engineering, discovered the way fibroblasts, or common cells in connective tissue, interact with the extracellular matrix, which provides structural support as well as biochemical and biomechanical cues to cells. The team uncovered a recursive process that goes on between the cells and their environment as well as structures in the cells that were previously unknown.

Results of the research were published in ACS Nano on July 28. Senior authors on the paper are Guy Genin, the Harold and Kathleen Faught Professor of Mechanical Engineering at the McKelvey School of Engineering, and Elliot Elson, professor emeritus of biochemistry and molecular biophysics at the School of Medicine.

Clinical efforts to prevent the progression of fibrocontractile diseases, such as scarring and fibrosis, have been largely unsuccessful, in part because the mechanisms that cells use to interact with the protein fibers around them are unclear, Shakiba said. We found that fibroblasts use completely different mechanisms in the early and I think the most treatable stages of these interactions, and that their responses to drugs can therefore be the opposite of what they would be in the later stages.

Genin, who is the co-director of the CEMB, said the process has stymied mechanobiology researchers for some time.

Researchers in the field of mechanobiology thought that cells pulled in collagen from the extracellular matrix by reaching out with long protrusions, grabbing it and pulling it back, Genin said. We discovered that this wasnt the case. A cell has to push its way out through collagen first, then instead of grabbing on, it essentially shoots tiny hairs, or filopodia, out of the sides of its arms, pulls in collagen that way, then retracts.

Now that they understand this process, Genin said, they can control the shape that a cell takes.

With our colleagues at CEMB at the University of Pennsylvania, we were able to validate some mathematical models to go through the engineering process, and we now have the basic rules that cells follow, he said. We can now begin to design specific stimuli to direct a cell to behave in a certain way in building a tissue-engineered structure.

The researchers learned they could control the cell shape in two ways: First, by controlling the boundaries around it, and second, by inhibiting or upregulating particular proteins involved in the remodeling of the collagen.

Fibroblasts pull the edges of a wound together, causing it to contract or close up. Collagen in the cells then remodels the extracellular matrix to fully close the wound. This is where mechanobiology comes into play.

Theres a balance between tension and compression inside a cell that is newly exposed to fibrous proteins, Genin said. There is tension in actin cables, and by playing with that balance, we can make these protrusions grow extremely long, Genin said. We can stop the remodeling from occurring or we can increase it.

The team used a 3D-mapping technique the first time it has been applied to collagen along with a computational model to calculate the 3D strain and stress fields created by the protrusions from the cells. As cells accumulated collagen, tension-driven remodeling and alignment of collagen fibers led to the formation of collagen tracts. This requires cooperative interactions among cells, through which cells can interact mechanically.

New methods of microscopy, tissue engineering and biomechanical modeling greatly enhance our understanding of the mechanisms by which cells modify and repair the tissues they populate, Elson said. Fibrous cellular structures generate and guide forces that compress and reorient their extracellular fibrous environment. This raises new questions about the molecular mechanisms of these functions and how cells regulate the forces they exert and how they govern the extent of matrix deformation.

Wound healing is a great example of how these processes are important in a physiologic way, Genin said. Well be able to come up with insight in how to train cells not to excessively compact the collagen around them.

See the rest here:

Researchers uncover how cells interact with supporting proteins to heal wounds - Washington University in St. Louis Newsroom

Strata Oncology Announces Partnership with BioMed Valley Discoveries to Accelerate Enrollment in ERK Inhibitor Study – BioSpace

ANN ARBOR, Mich., July 29, 2020 /PRNewswire/ --Strata Oncology, Inc. , a precision oncology company advancing molecular indications for cancer therapies, today announced it has signed an agreement with BioMed Valley Discoveries Inc.. to accelerate patient identification and enrollment for BioMed Valley's Phase 2 study of BVD-523 (ulixertinib) for patients with advanced malignancies harboring MEK or atypical BRAF alterations (non-BRAF V600E mutations).

Ulixertinib is a first-in-class potent and selective small molecule inhibitor of ERK1/2. BioMed Valley reported positive preliminary Phase I data for ulixertinib in patients harboring MAPK alterations, including atypical BRAF alterations.

Under the terms of the agreement and through the Strata Trial, Strata Oncology will identify patients with advanced solid tumors that harbor mutations in the MAPK signaling pathway and meet other eligibility criteria, for consideration of enrollment into BioMed Valley's Phase 2 study. The Strata Trial, an ongoing observational study providing tumor molecular profiling for patients with advanced cancer paired with a portfolio of biomarker-guided clinical trials, is available across a network of 25+ select health systems nationwide. Through the Strata Trial, patients with advanced cancer are profiled using StrataNGSTM, a comprehensive molecular profiling test optimized for performance on tissue samples as small as 0.5mm2 surface area.

"This partnership with BioMed Valley Discoveries supports our commitment to improving the lives of patients with cancer by providing local access to promising investigational therapies," said Dan Rhodes, Ph.D., CEO of Strata Oncology. "We are confident our network of health system partners, standardized on the Strata Trial, will help drive rapid enrollment of this important study."

David Chao, President & CEO of BioMed Valley Discoveries, commented,"We are delighted to collaboratewith Strata to developourfirst-in-class ERK inhibitor. Strata's ability to rapidly identify patients with specific tumor mutations has the potential to dramatically accelerate the recruitment of patients for our trial."

For more information about BioMed Valley's BVD-523 study, please visit clinicaltrials.gov.

About Strata OncologyStrata Oncology, Inc. is a precision medicine company dedicated to transforming cancer care by building a platform to systematize precision oncology across a network of health systems and pharma companies. Strata empowers health systems to deliver a cost-effective, system-wide, precision oncology program, one that integrates cutting-edge molecular profiling and precision therapy trials with routine care, so that all advanced cancer patients have the opportunity to benefit. This large network of trial-ready health systems provides a mechanism to rapidly and predictably enroll precision therapy trials. For more information visitwww.strataoncology.com.

Strata Inquiries:Renee Volpini(917) 923-8117renee.volpini@icrinc.com

View original content:http://www.prnewswire.com/news-releases/strata-oncology-announces-partnership-with-biomed-valley-discoveries-to-accelerate-enrollment-in-erk-inhibitor-study-301101635.html

SOURCE Strata Oncology, Inc.

Read the rest here:

Strata Oncology Announces Partnership with BioMed Valley Discoveries to Accelerate Enrollment in ERK Inhibitor Study - BioSpace

BioMed Valley Discoveries ulixertinib (BVD-523), a first-in-class ERK inhibitor cancer therapy, receives Fast Track designation and launches Phase II…

Newswise Kansas City, MO. BioMed Valley Discoveries (BVD), a clinical stage biotechnology company, announces the receipt of Fast Track designation from the US Food and Drug Administration (FDA) for investigation of the ERK inhibitor ulixertinib (BVD-523) as a treatment for patients with non-colorectal, solid tumors that harbor BRAF mutations G469A/V, L485W, or L597Q. BVD has launched a Phase II multi-center study of ulixertinib for patients with advanced malignancies harboring these atypical (non-V600) BRAF alterations or a MEK alteration.

The Phase II effort builds on a successful Phase Ib evaluating ulixertinib as a novel targeted cancer treatment in cohorts of patients with specific genetic alterations that result in aberrant MAPK pathway signaling. Results from Phase Ib showed that ulixertinib has an acceptable safety profile and early evidence of clinical activity against a wide range of tumor types exhibiting mutations in the MAPK pathway, including atypical alterations in BRAF.

BVD is pleased to announce that Cmed, Inc., will serve as the contract research organization (CRO) for the Phase IIb study. BVD is also collaborating with Strata Oncology to identify and obtain study patients with Stratas Precision Oncology Network. This network of trial-ready health systems features a database of matched trial candidates that will allow for rapid and efficient identification of potential patients.

David Chao, PhD, president and CEO of BVD, comments, We are pleased with the receipt of Fast Track designation for ulixertinib and delighted to collaborate with Cmed and Strata to develop this promising first-in-class ERK inhibitor.

This study (NCT04488003) is currently expected to begin enrollment in Q3 2020.

About ulixertinib(BVD-523): Ulixertinib is a first-in class and best-in class small molecule inhibitor ofextracellular signal-regulated kinase (ERK)family kinases (ERK1 and ERK2) thatis being developedas a novel anti-cancer drug. ERK kinases are downstream components of themitogen-activated protein kinase (MAPK)signaling cascade (RAS-RAF-MEK-ERK). Ulixertinib has demonstrated promising early efficacy for patients with tumors harboring alterations in the MAPK pathway, including atypical (non-V600) BRAF alterations, for which there are currently no approved targeted agents.

About Fast Track status: Fast Track is a designation by the FDA of an investigational drug for expedited review to facilitate development of drugs which treat a serious or life-threatening condition and fill an unmet medical need. Fast Track status entails eligibility for Accelerated Approval and Priority Review if certain criteria are met as well as more frequent interactions with the FDA.

About the study: This Phase II study expands upon the ulixertinib Phase I signal to evaluate the utility of ulixertinib to treat patients with tumors harboring an atypical BRAF alteration. Furthermore, the potential to treat MEK1/2 mutant cancers will also be explored. This patient population is rare (<1% of cancers), however a strong scientific rationale exists to treat patients harboring putatively activating MEK1/2 alterations with ERK inhibition. Part A of the trial is tumor histology agnostic, with patients enrolled in one of six groups based on their tumor alteration. Part B of the trial is tumor histology specific, enrolling patients with one of up to three specified tumor histologies based on evolving part A data.

About Cmed: Cmed, established for 20 years, is a global technology-led full-service CRO specializing in complex disease areas, particularly oncology, immuno-oncology, cell therapy, and other specialty therapeutics areas. Cmed has built a reputation for delivering these clinical trials with expertise, and a personalized, flexible approach, and a mission to contributing to the development of innovative medicines for the benefits of the patients. Cmed has a strong data management and statistics heritage. As well as being a Functional Service Provider of these services, via its Cmed Technology business (part of Cmed Group), Cmed has developed and uses an advanced, enterprise, cloud based clinical data system,encapsia.encapsiadelivers a complete solution to gather and manage multiple live clinical data sources and apply real-time data management, sophisticated visualizations, analytics, and AI. Client benefits include informed trial progress, deep insights into their data to support timely management decisions, and particularly relevant with the disruption caused by the COVID-19 pandemic, able to support remote, decentralized, and virtual trial conduct. For more information, visitwww.cmedresearch.comandwww.encapsia.comor contactInfo@cmedgroup.com.

About Strata Oncology: Strata Oncology, Inc. is a precision medicine company dedicated to transforming cancer care by building a platform to systematize precision oncology across a network of health systems and pharma companies. Strata empowers health systems to deliver a cost-effective, system-wide, precision oncology program, one that integrates cutting-edge molecular profiling and precision therapy trials with routine care, so that all advanced cancer patients have the opportunity to benefit. This large network of trial-ready health systems provides a mechanism to rapidly and predictably enroll precision therapy trials. For more information, visit http://www.strataoncology.com.

About the Strata Precision Oncology Network: The Strata Precision Oncology Network (Network), led by Strata Oncology, is a collaborative network of leading health systems that believe in deploying a clinical-research driven model for precision medicine that enables continuous learning to drive research and clinical care. The Network consists of 25 leading health systems that have demonstrated a commitment to standardizing tumor molecular profiling and precision therapy trials, providing a platform to accelerate drug approvals and catalyze new clinical research opportunities. The Strata Trial serves as the foundation of this approach by providing a standardized genomic testing protocol to deliver precision oncology system-wide.

About BioMed Valley Discoveries (BVD): BioMed Valley Discoveries is a clinical stage biotechnology company focused on addressing unmet medical needs in a variety of therapeutic and diagnostic areas. In addition to the ERK inhibitor, BVDs portfolio includes an oncolytic bacteria that has completed enrollment for a Phase I study, a selective phosphoinositide 3-kinase gamma inhibitor in late preclinical testing, and two early-stage antibodies targeting the tumor microenvironment.

Operating since 2007, BioMed Valley Discoveries was established by Jim Stowers Jr., founder of the asset management firm American Century Investments, and his wife Virginia, to advance new medical innovations to improve the lives of patients with difficult-to-treat diseases. BVD is owned by a supporting organization of the Stowers Institute for Medical Research, a non-profit, basic biomedical research organization. Since 2000, the endowment of the Stowers Institute has received over $1.5 billion in dividend payments from American Century. The Institute has invested a portion of its endowment in BVD, whose profits accrue to the benefit of the Institute. For more information, visit http://www.biomed-valley.com.

Link:

BioMed Valley Discoveries ulixertinib (BVD-523), a first-in-class ERK inhibitor cancer therapy, receives Fast Track designation and launches Phase II...

CENTOGENE and Molecular Health Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs – BioSpace

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and HEIDELBERG, Germany, July 27, 2020 (GLOBE NEWSWIRE) -- CentogeneN.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, and Molecular Health, a leading company in the field of data and computing science for precision medicine, announced today that they will collaborate exclusively to initiate the Real-life data and Innovative Bioinformatic Algorithms (RIBA) project starting with Epilepsy as the first indication. RIBA aims to foster a unique novel precision medicine environment to accelerate, de-risk, and improve the development of new orphan drugs based on the combination of large real-life data sets in rare disease with innovative big data, innovative artificial intelligence, as well as computational algorithms and expertise. Both companies are convinced that this strategy of merging real-life data with a global curated biomedical knowledge, as well as applying artificial intelligence and scientific computing will radically change and transform biomedical research, product development, and therapy. Additionally, it will offer data-/computing-driven solutions to guide the highest and most precise innovation for the new way of drug development in a modern biopharmaceutical environment.

Prof. Arndt Rolfs, CENTOGENE Chief Executive Officer, stated, We are excited about this collaboration. Both companies have been analyzing the potential interaction for an extended period of time and are deeply convinced that now is the right time to start an exclusive cooperation focusing on rare genetic diseases. The complementary expertise and knowledge of both companies will allow us to reduce the time to develop a new orphan drug by combining of real-life data and innovative computational biomedical expertise. CentoMD, one of the worlds largest rare disease data repositories, allows us to take advantage of the high quality of the real-life data from a global cohort of more than 500,000 consented patients. The extraordinary expertise of Molecular Health will not only speed up the identification of new targets in rare disease, but also allow us to de-risk and accelerate the development of new orphan drugs.

By starting this exciting collaboration between our companies, we are initiating and building a unique novel model of personalized healthcare. The combination of both companies data and expertise will ultimately transform modern drug development and therapy. It will allow for the development of better drugs with higher specificity and safety, lower attrition rates in clinical studies, and a faster time to market to help patients with severe diseases worldwide through novel therapies, said Dr. Friedrich von Bohlen, Molecular Health Chief Executive Officer. Together with CENTOGENE, Molecular Healths deep scientific, medical, and computational expertise will lay the fundament for personalized healthcare options in rare diseases to fulfill the promise of precision medicine.

The companies have agreed to start with Epilepsy as the first indication. Financial details were not disclosed.

About CENTOGENE

CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with approximately 3.0 billion weighted data points from over 530,000 patients representing over 120 different countries as of March 31, 2020.

The Companys platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners ability to bring orphan drugs to the market. As of March 31, 2020, the Company collaborated with 39 pharmaceutical partners covering over 45 different rare diseases.

About Molecular Health

Molecular Health is a data science-focused artificial intelligence computing company enabling and improving decision making in precision medicine for healthcare organizations. The company offerings are based on the capture, curation, integration, and analysis of large biomedical and drug data sets and combining them with novel artificial intelligence and machine learning (AI/ML) technologies.

For more than a decade, the company has been developing Dataome, a unique high-quality curated, interoperable system that combines clinico-molecular and drug data with proprietary analytical processes. Dataome stand alone or in combination with customer data enables the unlocking of actionable intelligence at the molecular level to a) improve diagnosis and therapy decisions by physicians and patients; b) enrich and support better drug discovery, drug development, trial optimization, drug differentiation and positioning for pharma and healthcare organizations; and c) more accurately predict the likelihood of success and likelihood of approval of drug candidates in clinical development for better trial prioritization and resource and investment allocation. For more information, visit http://www.molecularhealth.com.

Important Notice and Disclaimer

This press release contains statements that constitute forward looking statements as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Companys opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as anticipate, intend, believe, estimate, plan, seek, project or expect, may, will, would, could or should, the negative of these terms or similar expressions. Forward looking statements are based on managements current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, such as negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Companys control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please refer to the Risk Factors section in our Annual Report for the year ended December 31, 2019 on Form 20-F filed with the SEC on April 23, 2020 and other current reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at http://www.sec.gov.

Follow this link:

CENTOGENE and Molecular Health Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs - BioSpace

Three Faculty of Medicine researchers to study long-term effects of COVID-19 on children – UBC Faculty of Medicine

Dr. Michael Kobor, department of medical genetics, Dr. Brett Finlay, department of biochemistry and molecular biology, and Dr. Sara Mostafavi, department of medical genetics, are part of a cross-disciplinary team that received funding from the Manulife CIFAR Population Health & Well-being Grant Program.

The grant provides funding for CIFAR Program Members to study various social, behavioural, and public health-related aspects of COVID-19.

The team of 11 researchers are looking into how COVID-19 will affect childrens brains, immune system, and ability to thrive.

Dr. Michael Kobor

I am grateful to CIFAR and Manulife for funding this project, says Dr. Kobor. These funds will enable us to develop an integrative Society to Cell approach to understand the hidden costs of COVID-19 on childrens health and well-being. As Canada plans for recovery, policymakers need to make evidence-based decisions to ensure that children are not unintended casualties of the pandemic.

This project titled A bio-ecological integrative approach to understand the hidden costs of COVID-19 on children is one of six new COVID-19 and population health research projects that will offer new insights into the effects of the pandemic.

Dr. Brett Finlay

We know that changes to childrens environments can have profound impacts on their biology and health, says Dr. Finlay. This funding will bring together an international team of expert researchers across disciplines. Its imperative to understand the long-term impact of the COVID-19 experience on children so that inclusive policies can be implemented to support the next generation.

The team will integrate biological, behavioural, and sociological data to assess the long-term effects of the pandemic on children.

Dr. Sara Mostafavi

Using machine learning, big data integration and artificial intelligence, we can develop models for combining evidence across multiple types of data from multiple research groups aimed to understand child health and well-being, says Dr. Mostafavi, also a Canada CIFAR AI Chair.

The project is derived from the work that Drs. Kobor, Finlay and Mostafavi have collaborated together on as part of the UBC Social Exposome Cluster.

See the original post:

Three Faculty of Medicine researchers to study long-term effects of COVID-19 on children - UBC Faculty of Medicine

Portugal invented an innovative mask against coronavirus – FREE NEWS

Scientists from the Institute of Molecular Medicine in Lisbon announced the invention of a mask that not only protects against coronavirus infection but also neutralizes a harmful virus that has got on its surface, according to the Spanish edition of La Razon.

As explained by the representative of the institute Joo Lobo Antunes, the mask was the result of the joint work of Portuguese scientists. The positive effect is achieved thanks to several waterproof layers that make up the invention, and a special innovative fabric with a special coating.

According to virologist Pedro Simas, scientists studied the properties of the mask by immersing it in a solution containing coronavirus molecules. So they found out that 99% of the molecules that hit the surface lose their properties after an hour.

Antunes added that the mask is reusable. Experiments, which were carried out, including at the French Institute of Pasteur, have shown that it can be washed at least 50 times.

At the same time, La Razon does not specify when the innovative mask will be available to ordinary people.

According to the Portuguese publication Jornal de Noticias, over the past 24 hours, 263 new cases of coronavirus have been detected in Portugal, four people (aged 70 to 80) have died. Most of the new infections were recorded in the Lisbon area. At the same time, the authorities indicate that the number of hospitalized people throughout the country is gradually decreasing and now amounts to 460 people.

Link:

Portugal invented an innovative mask against coronavirus - FREE NEWS

Scientists have created a mask that kills coronavirus – The Saxon

Valery LEBOVKA, FACTS

Following the Israeli scientists who created the reusable protective mask that cleans itself from charging for phone, about the unique development of the scientists said, and Portugal.

In particular, the development of announced Institute for molecular medicine in Lisbon, writes TASS with reference to the newspaper La Razn.

Specifies that reusable cloth mask coated with a special compound that neutralizes the pathogen. The effect persists even after 50 washings. The idea belongs to several companies: the textile manufacturer Adalberto, retailers MO and Sonae Fashion and CITEVE technological centre and two universities Institute of molecular medicine and State University of Minho.

The material consists of several layers of different waterproof fabrics, which are impregnated with the composition, destroying SARS-CoV-2. He pushes a large part of pathogen that enters the saliva that allows you to erase the mask less often.

MOxATech (the so-called mask) went on sale in Portugal in April, but its effectiveness has not been confirmed by tests. Now the authors tested its ability to neutralize the virus. During the experiments the tissue was immersed in a solution that contained a certain amount of pathogen, and then measured its viability after contact with the material.

A virologist from the Institute of molecular medicine Pedro SIMAS, who coordinated the tests, said that the experiments showed effective neutralization of SARS-CoV-2 even after 50 washings. The concentration of the composition which permeates the fabric were not changed after treatment with cold water.

Scientists also observed the reduction of viral activity by 99% after contact with the tissue. The compound effectively killed almost all bacteria and fungi on the surface of the material. The Pasteur Institute in France, in independent experiments have proved that it is also effective against H1N1 flu virus, as anti-SARS-CoV-2.

The mask has been certified by the French leaders Gnrale des Entreprises. The company noted that the material after a large number of washings consumes about 96% of harmful particles.

Authors of technology talked about some of the features of the mask in the presentation. According to them, to store it, it is not necessary to observe special conditions: tests have shown that lighting, temperature and humidity do not affect the effectiveness of the composition. In addition, over time the protective properties are lost and the composition is not tolerated on the skin or clothing during wear.

The developers said that when you create a mask focused on average people. It can also carry doctors, but it does not meet all medical standards, so wear a mask as part of the working clothes in hospitals is not recommended.

While the mask is only sold in EU countries, distribution rights are owned by MO, whose specialists participated in developing. It is expected that in the future the product will appear in stores outside Europe, including in Ukraine.

Earlier, the FACTS wrote that in India a man for protection against coronavirus bought a gold mask over 4 thousand dollars.

Here is the original post:

Scientists have created a mask that kills coronavirus - The Saxon

Is red wine good for your heart? Yes, but only in moderation here’s how much you should drink – Insider – INSIDER

Research has found that drinking red wine in moderation can be good for your heart. However, consuming too much red wine, or any alcohol, is particularly bad for your heart, and can increase your risk for heart disease.

Here's what you should know about the heart benefits of red wine and how much of it is considered healthy.

The link between red wine and a healthy heart may be due to the high level of micronutrients, called polyphenols, found in the skin and seeds of grapes.

During the production process, red wine is fermented with the grape skins and seeds for a longer period of time than white wine, which means the polyphenols are much more concentrated. For example, a glass of red wine contains around 10 times more polyphenols than a glass of white wine.

These polyphenols especially a polyphenol called resveratrol have been shown to protect and support heart health.

The polyphenols in red wine have antioxidant properties. This means they prevent or reduce the oxidation of low-density lipoproteins (LDLs), the "bad" type of cholesterol molecules we carry in our bloodstream.

When LDLs are oxidized, they build up in the walls of our arteries and narrow them, so that less blood and oxygen can reach the heart. This can cause coronary heart disease, the most common type of heart disease, and the leading cause of death in the US.

Moderate consumption of red wine can also increase the level of high-density lipoprotein (HDL), or the "good cholesterol" in our blood, which is associated with a lower risk of cardiovascular disease. HDL cholesterol is good because it helps remove excess LDL cholesterol from the blood vessels.

For example, a small controlled study published in the journal Atherosclerosis in 2006 found that after drinking 400 ml (about two to three glasses) of red wine every day for six weeks, LDL cholesterol decreased by 8% in postmenopausal women who had high LDL levels, while HDL cholesterol increased by 17%.

Another study published in 2005 in the European Journal of Clinical Nutrition found that four weeks of moderate red wine consumption daily 300 ml for males and 200 ml for females increased levels of HDL cholesterol by a greater amount than drinking the non-alcoholic, wine-equivalent dose of red grape extract tablets with water.

Some research has found that drinking red wine may decrease platelet aggregation, which can also help reduce your risk for cardiovascular disease.

Platelets are tiny cells in our blood that bind together around damaged blood vessels when we become injured. This clotting is what stops us from bleeding and helps us heal when we get a minor cut.

However, when platelets aggregate too much, they can form blood clots. Blood clots are serious because they can block the flow of blood and oxygen to vital organs, increasing your risk of having a heart attack or stroke.

By reducing the stickiness of the platelets in your blood, red wine can help prevent blood clots and reduce your risk for health complications. For example, a 2002 study published in the International Journal of Molecular Medicine measured platelet aggregation levels in male volunteers after moderate wine consumption and found they were significantly inhibited.

In order to receive the heart health benefits of red wine, the American Heart Association (AHA) recommends no more than one drink a day for women and two a day for men. For reference, one drink is equal to five ounces, or 140ml of wine.

Drinking too much wine, or any type of alcohol in excess, is very bad for your heart, says Robert A. Kloner MD, PhD, Chief Science Officer of Huntington Medical Research Institutes in Pasadena, California and Professor of Medicine at the University of Southern California.

That's because too much alcohol can cause high blood pressure and raise levels of triglycerides, which will increase your risk of heart disease, heart attack, or stroke.

Excessive drinking can also lead to heart failure a disease which makes it harder for your heart to pump blood around your body and atrial fibrillation, which is a type of arrhythmia where the heart beats quickly and irregularly.

Read more to learn about how different levels of alcohol consumption affect the heart.

Drinking several glasses of red wine throughout the week can be part of a heart healthy lifestyle. But in general, you shouldn't drink more than one or two glasses each night.

In addition, it's important to note that there are many other foods that contain the polyphenols found in red wine which may have the same heart health benefits. For instance, you can find resveratrol in grape juice, peanuts, cocoa, blueberries, and cranberries.

You don't need to drink red wine to have a healthy heart. But, if you like drinking red wine, the good news is that it may have some heart benefits just make sure you drink in moderation.

See original here:

Is red wine good for your heart? Yes, but only in moderation here's how much you should drink - Insider - INSIDER

Meet the Irish scientist behind Oxford’s coronavirus vaccine – IrishCentral

Irish scientist Adrian Hill is leading the global charge in the search for a coronavirus vaccine and his team of researchers at Oxford University is reportedly close to finding the much sought-after vaccine, but who is he? And how did he rise to a position of such prominence?

Born in Dublin, Hill was educated at Belvedere College and studied medicine at Trinity College before transferring to the University of Oxford in 1978 and completed his medical degree there in 1982.

His interest in vaccines and tropical medicine was inspired by an uncle who was a missionary priest in Africa.

He remained at Oxford for postgraduate studies thereafter and emerged with a Doctor of Philosophy degree in 1986.

From there, Hill joined the newly-created Weatherall Institute of Molecular Medicine at Oxford in 1988 and began working on immunogenetics in West Africa.

He subsequently became lead of an academic course on Human and Animal Vaccinology at Oxford and he now serves as Director of the Jenner Institute, an Oxford institute which develops vaccines and carries out clinical trials for diseases, including malaria and Ebola.

While Hill is slowly becoming a household name as the race to find a coronavirus vaccine ramps up, he had already cemented his growing reputation in the scientific community for his work on an ebola vaccine in 2014.

Hill's team lead the first clinical trial of an Ebola vaccine, targeting the outbreak of Ebola in West Africa.

Read more:WHO say Irish scientist's COVID vaccine is the "leading candidate"

His group has also developed malaria vaccines that were tested in clinical trials. The vaccine is currently in large-scale trials in children in sub-Saharan Africa and is one of the most promising vaccines against the disease.

Hill is an ardent believer in the power of molecular medicine to deliver new healthcare interventions for some of the poorest communities on the planet.

With the outbreak of the COVID-19 pandemic, however, Hill's priorities have shifted focus and he is now the leading candidate to develop a vaccine against the virus.

Early results from his team's initial trials have yielded extremely positive news and some reports speculate that the vaccine may be ready by as early as September.

The vaccine potentially offers "double protection" against the coronavirus, building up appropriate antibodies and T-cells in test subjects.

Multinational pharmaceutical company AstraZeneca has reportedly ordered over 400 million doses of the vaccine to distribute by September or October based on the results of the trials.

Hill's vaccine will now potentially head to "challenge trials", where researchers deliberately attempt to infect test subjects with the virus after they have been given a dose of the vaccine.

The Irish vaccinologist is also an accomplished writer, and his works have appeared in a variety of national media publications.

Hill has two children with his former wife, Sunetra Guptta who is also a well known Indian novelist, and professor of theoretical epidemiology at the University of Oxford with an interest in infectious disease agents.

The 61-year-old is clearly one of the brightest in his field and, right now, the world needs him to work some magic.

Read more: Irish scientist's coronavirus vaccine could be ready by September

Read the original post:

Meet the Irish scientist behind Oxford's coronavirus vaccine - IrishCentral

Dry- and wet-lab research ‘Big data’ brings two worlds together – Times of Malta

Big Data has become a staple of scientific endeavour. The phrase crops up repeatedly in common parlance. It has become a buzzword synonymous with scientific effort, experimental complexity and data reliability. This is because the field of Big Data offers ways how to deal with large datasets often originating from different experiments.

For example, an experiment to sequence your DNA may generate over 200GB of data. That is the size of two full-length 4K movies!

Big Data increases the robustness of any findings and reduces the odds of a result being only due to chance.

In molecular biology, if a scientific result is supported by various sources of data, such as DNA, protein and other molecular research, then it would be expected to provide a better overall understanding of the natural phenomena under study.

However, to generate and analyse such Big Data, scientists are required to train in both wet-lab and dry-lab techniques. Wet-lab scientists perform research on chemical and biological samples of various origins, including patients. Dry-lab scientists mine the large datasets generated from a multitude of experiments computationally. They combine all the elements together to identify trends, create models and provide unique insight that no single source of data can achieve.

This kind of research integration has many applications. Networks can be built to understand the relationships between genes or proteins. Libraries of synthesised compounds can be screened in search of potential drugs. Diagnostic biomarkers may be identified by combining DNA sequencing and protein datasets. On a large scale this is beneficial to patients in the form of earlier diagnosis, personalised treatment and improved outcome.

Modern biomedical research labs rarely conduct purely wet- or dry-research. The scientist of the 21st century needs to be skilled in both types of research. Thus, prospective biomedical students are encouraged to try their hand at both dry- and wet-lab techniques. This enables them to find their place in the research community of the future, doing research that they enjoy.

The University of Malta offers several courses which train students in dry- and wet-lab skills and research.

Jean Paul Ebejer is the coordinator for the Masters in Bioinformatics programme and performs research in bioinformatics and computer-aided drug design. Byron Baron is involved in the BSc for medical biochemistry and heads research in methylation proteomic analysis on cancer.

Both lecture and research at the Centre for Molecular Medicine and Biobanking of the University of Malta.

A groundbreaking study is the first to analyse the relationship between group behaviours, group type, group dynamics, and kinship of beluga whales in 10 locations across the Arctic. Results show that not only do beluga whales regularly interact with close kin, including close maternal kin, they also frequently associate with more distantly related and unrelated individuals. Findings will improve the understanding of why some species are social, how individuals learn from group members and how animal cultures emerge.

https://www.sciencedaily.com/releases/2020/07/200710212233.htm

Dinosaurs and flying pterosaurs may be known for their remarkable size, but a newly described species from Madagascar that lived around 237 million years ago suggests that they originated from extremely small ancestors. The fossil reptile, named Kongonaphon kely, or tiny bug slayer, would have stood just 10 centimetres tall. The description and analysis of this fossil and its relatives, published in the journal Proceedings of the National Academy of Sciences, may help explain the origins of flight in pterosaurs, the presence of fuzz on the skin of both pterosaurs and dinosaurs, and other questions about these charismatic animals.

https://www.sciencedaily.com/releases/2020/07/200706152659.htm

For more soundbites listen to Radio Mocha every Saturday at 7.30pm on Radju Malta and the following Monday at 9pm on Radju Malta 2. https:// http://www.fb.com/RadioMochaMalta/

The National Gallery in London was only shut for two days during World War II, ironically during VE Day celebrations in May 1945.

You are not imagining it summer heat really does make people crankier.

The average garden snail has over 14,000 teeth.

Leonardo da Vinci was notorious for missing deadlines. Pope Leo X is reported to have said: This man will never accomplish anything, he thinks of the end before the beginning.

Eating too many carrots, pumpkin or citrus fruits can result in carotenosis, where your skin turns orange.

There are more trees on Earth than there are stars in the Milky Way. Until now.

For more trivia see: http://www.um.edu.mt/think

Independent journalism costs money. Support Times of Malta for the price of a coffee.

View post:

Dry- and wet-lab research 'Big data' brings two worlds together - Times of Malta

Queens partners with industry for COVID research – The Kingston Whig-Standard

Researchers at Queens University are working alongside companies to determine how best to respond to the various problems the ongoing COVID-19 pandemic has caused in Canada.

Two projects associated with Queens have received over $4 million through the Digital Technology Superclusters COVID-19 program: Project Looking Glass and Project ACTT.

The program focuses on funding technologies that support the health system, community health, safe living, diagnostics and therapeutics, and emergency COVID-19 response. It has provided a total of $60 million in funding to various projects.

The Superclusters initiative demonstrates what we can do when we harness the collective strengths of industry, academia. and research, Kimberly Woodhouse, vice-principal (research), told the Whig-Standard. Queens is a key partner in helping to grow these companies and collaborations and providing vital expertise that will help in our national efforts to combat COVID-19 through strength in digital technology.

Led by Kings Distributed Systems (KDS), Looking Glass: Protecting Canadians in a Return to Community is building a platform that will use predictive modelling to analyze pandemic policies and determine which ones are most effective.

Policy makers will be able to input possible actions and clearly see the potential outcomes, in terms of both public health and the economy. They will also be able to use the tools interactive map, which links demographic, economic, and COVID-19 case report data to specific census regions.

Queens mathematics researchers Troy Day and Felicia Magpantay will contribute leading epidemiological models to the project.

Queens Partnerships and Innovation (QPI) has provided some of the projects industry partners with supports, including the facilitation of a pilot project with Queens Centre for Advanced Computing. One of these industry partners, Limestone Analytics, is led by Queens professor Bahman Kashi.

With partners and contributors from a range of institutions and industry across Canada, this diverse collaboration with develop Looking Glass into a powerful tool to forecast not only COVID-19 infection rates from actions such as reopening schools, but also other critical public health issues like vaccination campaigns and managing tick-borne disease, the university wrote in a statement.

Led by Canexia Health, Project ACTT: Access to Cancer Testing and Treatment in Response to COVID-19 focuses on expanding access to cancer testing, which has been delayed through the pandemic as a result of limits placed on non-COVID care.

The project will use a minimally invasive DNA test as an alternative to surgical tissue biopsies. The test takes a blood sample from the patient and analyzes it to detect fragments of DNA shed by cancer tumours.

This method functions as a remote delivery substitute for cancer biopsies, thus minimizing patient exposure to COVID-19. It may also provide solutions for testing those in rural or remote areas.

The projects principal investigator is Queens pathology and molecular medicine researcher Harriet Feilotter, who is also a member of the Queens Cancer Research Institutes Division of Cancer Biology and Genetics.

In response to COVID-19 many Queens researchers have been building on their industry partnerships to help rapidly pivot and mobilize their research to address some of the many complex problems posed by the pandemic, the University wrote. Many collaborations have been formed to help not only respond to immediate issues, but to also look to the future as we assess the crisiss impact throughout society.

View original post here:

Queens partners with industry for COVID research - The Kingston Whig-Standard

Why we need to fix the healthcare system: An interview with Dr Mikashmi Kohli – Hyderus Cyf

There is a need for proper planning and strengthening the healthcare system where both the pandemic and these other treatable diseases can be managed simultaneously, Dr Mikashmi Kohli told me recently. We now have diagnostic tools which are multi-disease platforms so focusing just on COVID-19 , while forgetting about patients suffering from these manageable diseases, will only lead us in the direction of a failure.

One of the main consequences of the COVID-19 pandemic has been the neglect of the treatment of other diseases and disruptions to health systems. I spoke with Dr Kohli a postdoctoral fellow in the Department of Epidemiology, Biostatistics and Occupational Health at McGill University on a range of topics. We discuss how COVID has disrupted health systems; how other diseases are being neglected; and the work we need to do to strengthen health systems going forward.

We cant just think unilaterally, Dr Kohli told me earlier this month. The disruption has been a problem of a broken healthcare system and it is imperative to start fixing that.

You can watch our interview here.

Dr Mikashmi Kohli is a postdoctoral fellow at McGill University, Canada. She completed her PhD in Molecular Medicine from the All India Institute of Medical Sciences, New Delhi. Having worked in India on diagnosis of TB, especially extrapulmonary TB, she developed a strong interest in diagnostics and EPTB research.

Currently, she is working on understanding the availability and access to diagnostics in primary healthcare settings in LMICs and ways to improve the diagnostic landscape in these countries. She has also been working with the Cochrane Systematic Review team on diagnostic accuracy of molecular tests in TB. She is passionate about diagnostics in Global Health and implementation of basic science research in the global health scenario.

You can watch and read Health Issues Indias other interviews with thought leaders in health and development here.

You can read my previous interview with Dr Kohli on diagnostics and UHC here.

Like Loading...

Related

Read the rest here:

Why we need to fix the healthcare system: An interview with Dr Mikashmi Kohli - Hyderus Cyf

Precision Medicine Market 2019 | Current Trends And The Future Growth | Forecast Till 2025 – Owned

Overview:

The report on a global scale regarding the precision medicine market would witness a rise by 12.48% CAGR during the forecast period encompassing 2019-2025 to reach and surpass a valuation by USD 126.14 billion. Market Research Future (MRFR) revealed that this growth would be substantial due to the inclusion of high throughput sequencing, increasing expenditure from several private companies and governments, development in the structure of the healthcare sector, better participation from pharmaceutical companies, growing rate of chronic diseases, and others. High chance of recovery would also trigger better precision medicine market expansion in the coming few years.

Segmentation:

The global market report on precision medicine can be segmented into ecosystem players, sub-markets, and therapeutics. This is to facilitate a proper study that would determine the growth of the global market in the coming years.

By ecosystem players, the report on the globalprecision medicine marketcan be segmented into diagnostic companies, healthcare IT specialists/big data companies, pharmaceuticals and biotechnology companies, and clinical laboratories. The diagnostic tool companies segment has a substantial opportunity for growth from its previous valuation of USD 16.27 million in 2017.

By sub-markets, the global report on the precision medicine market can be segmented into companion diagnostics, targeted therapeutics, biomarker-based tests, molecular diagnostics, pharmacogenomics (PGX), and others.

By therapeutics, the global study containing the precision medicine market includes cardiovascular disease (CVD), cancer/oncology, infectious diseases, central nervous system, and others.

Browse Sample of the Report @https://www.marketresearchfuture.com/sample_request/925

Regional Market:

The market in America would lead the global scenario as it would be led by the US where the structure to support such researches are stronger than its peers. Along with it, the presence of Canada would boost the market outcome further. The regional market in the Northern part would see a constant flow of investment and a high inclusion rate of latest technologies. Better capacity to avail such methods would boost the market further. In the Southern region, this growth would be sluggish due to the presence of countries with poor infrastructure and investment capacity.

In Europe, growth would be backed by government initiatives to bolster the research facilities and investments from pharmaceutical companies. The latter is a common trait for both North America and Europe. In Asia Pacific, these companies would launch extensive expansion plans in growing economies where the healthcare sector is witnessing a surge in activities.

Competitive Analysis:

The global market report for precision medicine includes discussions regarding various types of strategic moves taken by top-players like Almac Group, Ltd., ABBOTT LABORATORIES, bioMrieux SA, ASURAGEN, INc., GlaxoSmithKline Plc (GSK), Cepheid Inc., CETICS Healthcare Technologies GmbH, GE Healthcare, Johnson & Johnson, Intomics A/S, Medtronic, Novartis, LABORATORY CORPORATION OF AMERICA HOLDINGS, Qiagen, Pfizer Inc, Randox Laboratories Ltd, BIOBASE GmbH (Subsidiary), Quest Diagnostics Inc., Sanofi Pharma, Takeda Pharmaceutical Company Limited, Roche Holding AG-Br, Caris Life Sciences, HealthCore, Inc., Teva Pharmaceutical Industries Ltd., Intel Corporation, Molecular Health GmbH, AB-Biotics SA, InnVentis, IBM, and Precision for Medicine. These players are known for their strategic moves like mergers, increasing investment in various research and development facilities, collaborations, and others.

Industry News:

In March 2020, researchers from Nemours Childrens Health System announced that they had identified a new type of variant in genetic structure that will help in manufacturing personalized drugs for patients with leukemia. Many researchers are looking at this as a possible counter-attack against the cancer. Researchers have suggested using next-generation sequencing that would increase precision in the detection of the process.

Browse More Details of the Report @https://www.marketresearchfuture.com/reports/precision-medicine-market-925

Read the original post:

Precision Medicine Market 2019 | Current Trends And The Future Growth | Forecast Till 2025 - Owned

Vaccines: What we know and what we don’t – Politico

With help from Myah Ward and Ryan Heath

NEEDLE IN A HAYSTACK Results from two front-running Covid vaccine candidates one from a joint Oxford University-AstraZeneca team, the other from Chinas CanSino Biologics were published today in the Lancet. The early results show that the two candidates produced an immune response in people.

Heres what we learned: The Oxford vaccine produced a promising immune response that lasted for nearly two months in an early study of more than 1,000 healthy adults. Likewise, most participants in a 500-person trial of CanSinos vaccine, which tested two dose strengths, showed an immune response.

Heres what we still dont know: What immunity to the virus looks like. Participants in both trials developed Covid-19 antibodies, and volunteers in Oxfords trial also produced more of the white blood cells known as T cells. Scientists think both antibodies and T cells could be important protectors against the virus, but they dont know what level of each we might need to fend off infection. Antibodies, produced by another type of white blood cell called B cells, are proteins that bind to foreign invaders like viruses to keep them from infecting our cells. T cells kill cells once they are infected.

Months into the pandemic, researchers are still learning how the immune system responds to the virus. No other viruses appear to provoke such a wide range of reactions. Up to 40 percent of people who are infected show no symptoms, while others suffer everything from lung failure to neurologic symptoms and die. Its an exceptionally different virus than any that appeared to date, said Eric Topol, executive vice president and professor of molecular medicine at Scripps Research Institute, a nonprofit biomedical research facility based in San Diego.

In other ways, this coronavirus is less tricky than other viruses: Compared to viruses like HIV the coronavirus has much less diversity on the genetic level, said Dave OConnor, professor of pathology and laboratory medicine at the University of Wisconsin. Its the same shape in nearly everyone. OConnor doesnt think that we will need a new vaccine every year like the flu because of virus shape changes, but we might need occasional boosters.

We still dont know whether Covid survivors can become reinfected, or how long their immunity to the virus lasts. But those questions could become irrelevant once a vaccine is discovered, said Akiko Iwasaki, a Yale immunobiologist. A vaccine is often better at producing long-term immunity than surviving an infection is. A vaccine, unlike a natural infection, can boost the immune response to the level where it becomes protective, said Iwasaki. In the end its really the efficacy that matters.

Heres what to look for next: CanSinos decision to use a weakened common cold virus as the base of its vaccine could undermine the shots effectiveness. The study today revealed that people who had previously been exposed to the cold virus showed weaker immune responses to the coronavirus vaccine presumably because their immune systems zeroed in on the familiar component of the vaccine, the weakened cold virus, rather than SARS-CoV-2.

Older people, whose immune systems are less vigorous, also showed a weaker response to the vaccine.

Large end-stage trials of both vaccines are underway in tens of thousands of people, and should reveal whether the shots work. Scientists will track rates of infection among people who get the vaccines versus those who dont. Results are expected in the next several months. Stay abreast of the latest developments with POLITICOs vaccine tracker.

Welcome to POLITICO Nightly: Coronavirus Special Edition. Anthony Fauci is throwing out the first pitch for the Washington Nationals season opener on Thursday. Reach out [emailprotected] or on Twitter at @renurayasam.

A message from Emergent BioSolutions:

Our global team is going full speed to develop potential therapies that may help treat COVID-19. At the same time, were collaborating on innovative vaccine candidates that can be made by the millions. Discover what were doing right now.

FOOD FIGHT The Trump administration is resisting calls to make it easy for tens of millions of students to get free meals at school this year, even as childhood hunger rates have risen to the highest levels in decades. During the spring and summer, as the coronavirus health crisis exploded, the government allowed most families to pick up free meals from whichever school was closest or most convenient without proving they are low-income, Helena Bottemiller Evich and Juan Perez Jr. write. But that effort is on the verge of expiring. School systems are pushing the federal government to continue the free meals program through the fall.

So far, Trumps Agriculture Department isnt on board. School leaders are now asking Congress to force the administrations hand as lawmakers buckle down to work on the next coronavirus aid package.

MORTALITY VS. FATALITY In an interview with Fox News Chris Wallace on Sunday, President Donald Trump said the U.S. has one of the lowest mortality rates anywhere in the world, while Wallace said the U.S. has one the worst. One reason for the confusion: Wallace was talking about mortality rates, while the president was referring to a measurement called the case fatality rate, Nightlys Myah Ward writes.

Whats the difference? The mortality rate is the number of Covid deaths among all people in a given population over a period of time. CFR measures the number of deaths among people with Covid. It is a measure of the diseases severity, how likely it is this might kill me, said Abraar Karan, a physician at Harvard Medical School and Brigham and Women's Hospital.

Mortality rate is kind of the standard terminology we use when were talking about how many people die from a disease, typically in the setting of chronic diseases, said Ellie Murray, a professor of epidemiology at Boston University School of Public Health.

And thats because if were thinking about something like cancer you have cancer, you dont have cancer, she said. But infectious diseases are a bit weirder than chronic diseases in that you can be infected and never really get the disease.

The news media and others not familiar with infectious disease often use mortality rate as an umbrella term, and this can be misleading, Murray said. So which measurement should we be using?

The Johns Hopkins data used by Wallace during the interview is really only useful for comparing between countries, Murray said, because it gives you the sense of, standardized to the population sizes of different countries, how big is the outbreak?

But to see how a country is doing with finding cases and treating sick people, look at the case fatality rate, Murray said. The more cases you find, the lower that number will go, she said. And so you can kind of get that case fatality rate number down by finding more mild cases and doing better treating the cases that you have.

BRIEFINGS ARE BACK Trump said today he would resume holding coronavirus briefings after a nearly three-month hiatus. A constant presence during the spring, the briefings were curtailed in late April. The last one featured Trumps unfounded speculation that injecting disinfectants could ward off the virus. Trump told reporters gathered in the Oval Office this morning that the next coronavirus briefing would likely be held on Tuesday at 5 p.m. Eastern time.

AT THE TABLE Trump and top administration officials are continuing to push for a payroll tax cut but Republican leaders on Capitol Hill havent signed off on the proposal as Congress begins work on a new coronavirus relief package, Marianne LeVine, Andrew Desiderio and John Bresnahan write.

Trump and Republican leaders in Congress are united on reducing unemployment insurance payments as part of their newest stimulus proposal, and they will call for additional direct payments to Americans as part of a $1 trillion package expected to be unveiled this week.

The negotiations kicked off today as lawmakers returned to Washington after a two-week recess that saw massive spikes in coronavirus cases in many states.

Senate Republicans are also pushing for tens of billions of dollars in funding for testing and additional funds for the CDC, in addition to spending boosts for the State Department and Pentagon money that the White House so far has resisted including in the new package. Trump administration officials have also floated new spending caps for next years budget, and they are seeking funding for non-coronavirus projects, such as $250 million for FBI renovations, said GOP lawmakers and aides.

STILL NOT CLOSE The sheriff of Jacksonville, Fla., said he cant provide security for the Republican National Convention because of a lack of clear plans, adequate funding and enough law enforcement officers, Marc Caputo writes. As we're talking today, we are still not close to having some kind of plan that we can work with that makes me comfortable that we're going to keep that event and the community safe, Duval County Sheriff Mike Williams told POLITICO.

Williams, a Republican, wouldnt definitively say there is no way the event could be held. But he said he had grave doubts about it, especially in an era of heightened protests concerning police use of force. Williams said the event, scheduled for Aug. 24-27, was announced in June, giving his agency little time to plan and prepare.

DeSANTIS, TEACHERS HEAD TO COURT Floridas largest teachers union sued Republican Gov. Ron DeSantis and state Education Commissioner Richard Corcoran to overturn a sweeping emergency order that requires schools to physically open five days a week, saying the policy bypasses local leaders and defies national public health guidelines, Florida education reporter Andrew Atterbury writes.

The complaint, filed in circuit court in Miami-Dade County, comes as the Republican governor sought to distance himself from the order, which was issued July 6.

DeSantis put the order squarely at Corcoran's feet today and said it was meant to give parents the option of sending their children back to school. I didnt give any executive order, that was the Department of Education, DeSantis told reporters.

A message from Emergent BioSolutions:

GETTING TESTED IN MIAMI Trade reporter Sabrina Rodriguez emails us:

After six months away from my 90-year-old abuela, I decided it was time to ditch D.C. and drive to Miami more specifically, my hometown of Hialeah, Fla., the U.S. city known for having the highest population of Cubans and Cuban Americans outside the Communist-run island.

It took a 15-hour drive, not including a couple breaks at sketchy rest stops. Once I made it, I went straight to a friends vacant apartment to isolate for a few days before going to get tested. I spent days on the phone and online trying to schedule an appointment through the Miami-Dade County Department of Health with no luck, so I resorted to driving to Miami Beach for an appointment-free, drive-thru testing site.

I braced for a massive wait after hearing about friends who sat in their car for more than three hours waiting for a test. But I was done within 50 minutes 25 minutes of which were spent in my car before a member of the Florida National Guard knocked on my window and asked if I wanted to park to take a walk-up test, where there were only six people in line.

That same member of the National Guard (who frankly was not very well versed in social distancing, and kept trying to hand out bottles of water with his bare hands) said the drive-thru line had stretched out about a mile, with a three-hour wait, earlier in the day.

Waiting for my results was another story. After six days, my results came via text message. I almost had completed a 14-day quarantine a day of driving, five days of trying to schedule a test, six days of waiting for my results by the time I found out I tested negative. Now, Im finally reunited with my abuela and my mother.

Nightly asks you: Have you gotten tested for Covid-19? Do you want to get tested but are unable to? Tell us your testing experience. Send us your story with our form and well include some of the responses in Fridays Nightly.

STILL VACANT Summer holidays along the Aegean Sea have always been popular in Europe, but Greeces large tourism economy hasnt seen much of a comeback, Nektaria Stamouli writes. The Greek government opened the countrys borders in mid-June, under pressure from the tourism sector, which makes up 20 percent of the countrys economy. While Greeces Covid numbers dont look bad 194 deaths and about 4,000 infections the move has forced mandatory mask-wearing in spaces like supermarkets starting this week, without anything like the economic boost tourism operators hoped for. Hotels are reporting occupancy rates at 30 percent or lower.

Parisians watch the opening night of a floating cinema in Paris. Thirty-eight electric boats were installed along the Seine river in compliance with social distancing rules, with 150 deckchairs on the banks of the canal, to screen films. | Getty Images

$35 million

The amount of money outside vendors have received for work on the new data system, HHS Protect, that the health department is using to restore public access to coronavirus data. Officials say they have implemented safeguards to prevent tampering, such as keeping a record of all changes that were made.

ADIOS TO OL? In bullfighting, the dying animal is put out of its suffering with a quick dagger blow by the puntillero. Now, after years of decline, the whole industry may be about to receive its own death blow at the hands of the coronavirus.

The pandemic struck Spain in March, just as the bullfighting season was about to get underway. A strict lockdown was introduced for the next three months, meaning the cancellation of all events, including major ones such as Sevilles Feria de Abril and San Isidro in Madrid. Although in recent weeks the country has returned to a normality of sorts, with businesses, theaters and cinemas reopening and top-tier football resuming, bullfighting is still in limbo.

This is a disaster of unprecedented dimensions, weve not seen a situation like this one in the history of bullfighting, said Antonio Lorca, who covers the sport for El Pas newspaper. Theres even a risk it will disappear altogether. Technically, bullfights are now allowed again, although regional governments must impose safety restrictions, such as limiting the number of people allowed to attend and ensuring there is social distancing between them. This and the uncertainty that reigned throughout the spring has meant that the vast majority of the summers events have been canceled.

A message from Emergent BioSolutions:

We go after public health threats. In the fight against COVID-19, we are going full speed to develop potential new therapies and vaccine candidates.We go for critical innovations. We are developing two potential hyperimmune treatments for severe hospitalized COVID-19 patients and individuals at risk. Based on proven technology, the research and testing are underway.We go in partnership with others. We are working with industry innovators to bring COVID-19 vaccine candidates to market. We have the capacity to manufacture vaccines in the tens to hundreds of millions, and we are propelling development forward.We go. And go. From fighting anthrax to helping prevent smallpox and developing vaccine candidates, we go all in. Because public health threats will never stop. And neither will we.

See how we go all in.

Did someone forward this email to you? Sign up here.

See the rest here:

Vaccines: What we know and what we don't - Politico

MicroGenDX Advances Research for Breakthrough Treatments of Urinary Tract Infections – Business Wire

ORLANDO, Fla.--(BUSINESS WIRE)--A first-of-its-kind study to help treat Urinary Tract Infections (UTIs) is underway through a research partnership with one of the worlds leading medical experts in treating UTIs and a company that uses advanced DNA technology to identify microbes that cause infection so that doctors can target precise medical treatment.

Dr. J. Curtis Nickel, Research Chair in Urologic Pain and Inflammation at Kingston General Hospital Kingston, Ontario, Canada, is working with MicroGenDX, an Orlando, Fla.-based company that operates a high complexity diagnostic laboratory, to establish a baseline for what microbes are present on normal urine that is urine from those not currently experiencing any type of infection.

"The future of managing infectious disease in Urology will involve determining the pathogenic ecology of the lower urinary tract obtained with non-culture molecular diagnostic technology, such as Next Generation Sequencing (NGS), said Dr. Nickel. Until we know what the normal microbiome looks like in healthy individuals, it will remain difficult to interpret NGS microbiome results from urine specimens submitted by symptomatic patients.

Other medical experts are also excited about this groundbreaking research. "Our microbiome plays a pivotal role in our health and survival, yet we really dont know what normal is for the urinary tract of men and women, said Dr. E. David Crawford, Professor of Urology at University of California San Diego. This is one of the most important clinical studies to date in this area. I encourage healthy individuals to be a contributor to this study.

UTIs are the most common outpatient infections in women today, according to a recent peer-reviewed article in Therapeutic Advances in Urology. UTIs will affect 5060% of adult women, with women over 65 experiencing almost double the rate as the female population overall. As many as one-in-five women suffer from recurrent UTIs, those that occur at least twice in six months or three times per year. While UTIs are more common among women, men can also fall victim to these stubborn infections. According to the National Kidney Foundation, UTIs account for some 10 million healthcare visits per year.

The driving force behind the study is MicroGenDX, which identified the need for this research, collaborated with Dr. Nickel in its design and managed the FDA-required Institutional Review Board process required for this type of medical research. Additionally, MicroGenDX is donating approximately $120,000 in lab services for collection, shipment and analysis of samples.

Our support of this research is a part of our ongoing effort to advance the science of detecting, identifying and treating viral, bacterial and fungal infections, said MicroGenDX CEO Rick Martin. We are honored to be working with the worlds leading experts and look forward to the findings of this study, which will help improve the lives of those suffering with recurrent UTIs.

In order to participate in the study, a person should be in good urological health and cannot have taken any antibiotic or antifungal medication for the past three months. Those wishing to participate in the study just need to complete an online questionnaire. Those selected for the study will be sent a urine collection kit, which can be used at home and returned in a prepaid package to MicroGenDX. There is no cost to participate, and each participant will receive his or her results. Those wanting to participate or learn more about the study can go to https://microgendx.com/healthymicrobiomestudy/. Researchers hope to conclude the study later this year.

About Dr. J. Curtis Nickel

J. Curtis Nickel, MD, FRCSC, is Professor of Urology and Research Chair in Urologic Pain and Inflammation at Kingston General Hospital Kingston, Ontario, Canada. He has over 550 publications, is on the editorial board of eight Urology journals, editor of the AUA Update Series, presented in 45 countries, funded by US NIH and Canadian CIHR and was awarded a CIHR Tier I Canada Research Chair (until 2021), AUA Distinguished Contribution Award and SIU Academy Award. He is currently Immediate Past-President of the Canadian Urological Association.

About MicroGenDX

MicroGenDX is a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvements Amendments (CLIA) licensed clinical laboratory with more than 12 years of experience in diagnosing molecular-based, laboratory-developed tests. MicroGenDX operates a high-complexity diagnostic laboratory that uses Next Generation DNA Sequencing Technology (NGS Technology) rather than the traditional approach of growing cultures to determine the presence of and identify by their genetic markers specific micro-organisms that are the cause of infections.

MicroGenDXs technology and mission are improving and saving the lives of patients with serious and often chronic infections and diseases by using the latest science and the most precise diagnostic tool available to identify the cause of infection so that the most effective medicine can be prescribed to treat that infection. Thousands of patients with chronic and often life-threatening infections have benefited from MicroGenDXs work.

The rest is here:

MicroGenDX Advances Research for Breakthrough Treatments of Urinary Tract Infections - Business Wire

Inactive medicine ingredients may be actively harmful, study warns – SlashGear

The inactive ingredients found in medication, including things like fillers and dyes, may not be as inactive as they seem, according to a new study. Some of these compounds may have an active effect on the body and, in some cases, may be harmful, the research suggests. Though inactive ingredients are often an important part of various drugs, the study suggests that additional research is necessary to determine their individual effects.

Medication is often composed of two types of ingredients: the active compound and excipients, which are inactive compounds used for things like delivering the active ingredients. In most cases, tablets and certain other types of medication contain more excipients than active ingredients, though that doesnt mean they arent a necessary part of the overall drug delivery.

The new study out of the American Association for the Advancement of Science warns that while most excipients are indeed inactive, some may have an impact on the parts of the body targeted by active ingredients, including things like receptors and enzymes.

The inactive ingredients are studied on animals for potential toxicity, but the new study warns that there isnt much research on whether these compounds also impact the medically relevant molecular targets. As part of the research, it was found that 38 approved inactive ingredients have 134 effects on molecular targets that were previously unknown.

Of particular relevance is that a minority of excipients may have a harmful effect, with the study noting that:

several excipients exhibit evidence predictive of tissue-level toxicity in cellular models. While most of these are suspected not to reach dangerous exposure levels, the results suggest that two thimerosal and cetylpyridinium are capable of reaching in vivo concentrations, that overlap their in vitro binding activity to the dopamine receptor D3.

Ultimately, the study found that additional research into the potential impact of these active ingredients toxicity aside is necessary to determine whether some inactive ingredients may have their own direct effects on the body.

Link:

Inactive medicine ingredients may be actively harmful, study warns - SlashGear

Progenity Reaches Resolution with Government Related to Past Business, Promotional, and Billing Practices – GlobeNewswire

SAN DIEGO, July 23, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company focused on providing complex molecular and specialized diagnostic tests to clinicians as well as innovating in the field of precision medicine, today announced that it has entered into agreements with the Department of Justice (DOJ) and the Department of Health and Human Services that resolve civil and criminal investigations by such agencies related to certain past business, promotional, and billing practices. After reviewing the Companys extensive remediation and cooperation efforts, among other considerations, the DOJ determined not to prosecute Progenity and instead entered into a non-prosecution agreement in parallel with civil settlements.

We are very pleased to resolve this matter as it allows us to move forward and concentrate on our mission to be a crucial provider of cutting-edge diagnostic testing and precision medicine, said Harry Stylli, PhD, CEO, chairman of the board, and co-founder of Progenity. Over the past two years, Progenity has implemented an overhaul of our compliance program and has transitioned from an out-of-network to primarily an in-network provider. These actions included engaging third parties to review our compliance policies and procedures, revamping internal controls to guarantee accurate and consistent coding, and changing our leadership team, including hiring a new Chief Compliance Officer, Chief Operating Officer, Chief Financial Officer, Chief Commercial Officer, and Chief Information Officer. We also appointed a new independent board with extensive industry experience in areas including reimbursement, regulatory, and compliance.

As described by the agreements, Progenity has committed to pay $35.8 million to settle the federal claims. Certain of the government agreements also obligate the Company to continue its enhancements to internal controls and its compliance program, while noting the Companys remediation and cooperation efforts to date. The Company expects to pay an additional $13.2 million to settle outstanding claims by state Attorneys General.

As the government recognized, Progenity has made significant strides in compliance policies and controls, accepting full responsibility for the historical misconduct at issue, said Stylli. Were excited to turn the page and focus fully on what we do best: providing valuable, industry-leading testing services to clinicians and developing our innovative precision medicine capabilities.

About ProgenityProgenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenitys vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. For more information on how Progenity is helping clinicians and patients prepare for life, please visit http://www.progenity.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the timing and amount of settlement payments and the effectiveness of Progenitys compliance protocols and reporting standards, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as may, might, will, objective, intend, should, could, can, would, expect, believe, design, estimate, predict, potential, plan or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that could cause the Companys actual results to differ materially from the forward-looking statements expressed or implied in this press release, including those described in Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations in Progenitys Registration Statement on Form S-1 (File No. 333-238738), as amended, filed with the U.S. Securities and Exchange Commission. Progenity claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Progenity expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law. Until the final settlement agreements are approved and signed by the states, there can be no assurance that the amount we have accrued will be sufficient to cover Progenitys obligations relating to this matter. Progenitys obligations could also increase, potentially materially, depending on a number of factors including whether or not the agreement on the monetary terms with the states is finalized, whether an individual state or states opt out of the settlement prior to approval in order to pursue a separate action or resolution, the terms of the final approved agreements and the parties to the settlement. For additional information, please see Note 9. Commitments and Contingencies to Progenitys audited financial statements for the year ended December 31, 2019, in the Registration Statement, as well as Risk FactorsRegulatory Risks Related to Our BusinessIf we or our commercial partners act in a manner that violates healthcare laws or otherwise engage in misconduct, we could face substantial penalties and our business operations, and financial condition could be adversely affected.

Investor Contact:Robert UhlManaging Director, Westwicke ICRIR@progenity.com(619) 228-5886

Media Contact:Kate Blom-LoweryCG Lifekblomlowery@cglife.com(619) 743-6294

Read the original:

Progenity Reaches Resolution with Government Related to Past Business, Promotional, and Billing Practices - GlobeNewswire